Efficacy and safety of Chinese Herb Medicine Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a prospective, randomized, controlled, open-label trial

Guangdong Provincial Hospital of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Meet the diagnostic criteria for patients with COVID-19 of the Proposal of Diagnosis and Treatment of COVID-19;
•(2) Aged 18-85 years;
•(3) To agree to participate in the study and sign the informed consent

•(1) Critical patients;
•(2) TCM diagnosis of yang deficiency syndrome, manifested as limb warm, thin stools, chills, etc.;
•(3) Patients who cannot guarantee compliance during treatment, and patients who are difficult to administer by oral or nasal route;
•(4) Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19;
•(5) Pregnant and mothers, those who have a pregnancy plan, and those who have a positive urine pregnancy test;
•(6) Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the study;
•(7) People who have been allergic to Chinese medicine or intolerant to taking medicine.
•(8) Patients are participating in other COVID-19 clinical trials.

发起方

Guangdong Provincial Hospital of Chinese Medicine